Welcome to our dedicated page for Neogenomics news (Ticker: NEO), a resource for investors and traders seeking the latest updates and insights on Neogenomics stock.
NeoGenomics, Inc. (NASDAQ: NEO) is a cancer diagnostics company focused on oncology genetics testing and information services. This news page aggregates company announcements, conference presentations, financial updates, and other disclosures that relate to NeoGenomics’ role in precision oncology and testing laboratories.
Readers can find earnings and financial news, including quarterly and preliminary full-year revenue updates furnished through press releases and Form 8-K filings. These items describe trends in clinical test volumes, next-generation sequencing (NGS) revenue, and other aspects of the company’s oncology testing business.
The news feed also features scientific and clinical research updates. NeoGenomics regularly announces data presentations at major oncology and hematology meetings, such as the San Antonio Breast Cancer Symposium, the American Society of Hematology Annual Meeting, the International Society of Liquid Biopsy Annual Congress, and the European Society for Medical Oncology Congress. These updates often highlight molecular residual disease (MRD) studies using RaDaR assays, comprehensive genomic profiling in myeloid malignancies, and liquid biopsy-based genomic profiling across solid tumors.
In addition, investors and clinicians can follow corporate and governance developments, including board appointments, executive transitions, and participation in investor conferences. Together, these news items provide a view into how NeoGenomics advances its oncology diagnostics platforms, supports pharmaceutical partners and academic collaborators, and manages its public-company responsibilities. For ongoing insight into NEO stock-related developments and oncology testing initiatives, this page serves as a centralized news resource.
NeoGenomics, Inc. has announced public offerings of approximately $200 million in common stock and $250 million in convertible senior notes due 2028. The offerings are not contingent on each other and are subject to market conditions. The convertible notes will bear interest and can be converted into cash or shares based on specific circumstances. Funds will be utilized for general corporate purposes and capped call transactions, with potential investments in complementary businesses. Market reactions may vary based on derivatives transactions related to these offerings.
NeoGenomics, Inc. (NASDAQ: NEO) will participate in the virtual 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 5:20pm ET. Key executives, including Chairman Douglas VanOort and CFO Kathryn McKenzie, will present. The event will be accessible via the company's investor relations website. NeoGenomics specializes in cancer genetic testing and offers extensive services globally, catering to pathologists, oncologists, and pharmaceutical firms. The company operates accredited laboratories in multiple U.S. locations and internationally in Switzerland and Singapore.
NeoGenomics, Inc. (NASDAQ:NEO) will participate in a virtual fireside chat at the Stephens Annual Investment Conference on November 17, 2020, at 9:00 AM ET. Key executives, including Doug VanOort (CEO) and Kathryn McKenzie (CFO), will be featured in the presentation, which will be webcast live and archived for 90 days. NeoGenomics specializes in cancer genetics testing and global oncology contract research services, operating accredited laboratories across the U.S. and internationally. The company remains focused on gaining new customers and implementing its business plan amidst the ongoing challenges posed by COVID-19.
NeoGenomics announced the launch of a mobile phlebotomy service for blood-based tests, including InVisionFirst-Lung and the NeoLAB suite. This initiative aims to enhance patient access to timely testing during the COVID-19 pandemic. Collaborating with ExamOne and Metro Health Staffing, NeoGenomics ensures convenient, in-home blood sample collection at no cost to patients. The service addresses safety concerns while maintaining continuity of care for cancer patients, with assays offering turnaround times of seven days or less.
NeoGenomics reported strong third-quarter 2020 results with consolidated revenue increasing by 20% to $125 million, and clinical services revenue up 17% to $109 million. Pharma services revenue rose 38% to $17 million, while backlog surged 57% to $185 million. Despite a less than 3% drop in average revenue per clinical test, gross profit increased by 6.4% to $54.1 million. Net income was $3 million, up from $2 million last year. Cash and equivalents totaled $265 million, showcasing the company's strong liquidity position.
NeoGenomics plans to open a new clinical research laboratory in Suzhou, China, in collaboration with PPD, Inc. The facility, spanning 67,000 square feet, aims to support clinical trials for both global and local pharmaceutical companies in Greater China. Expected to commence operations in 2021, this expansion highlights NeoGenomics' strategic growth despite the challenges posed by the COVID-19 pandemic, following their earlier expansion into Singapore. Company leadership emphasizes the increased capability to serve pharma clients efficiently in the oncology sector.
NeoGenomics, Inc. (NASDAQ:NEO) announced plans to release its third quarter 2020 financial results on October 27, 2020. A conference call and webcast are scheduled for 8:30 AM EDT on the same day to discuss the financial results. Investors can access the call by dialing (844) 602-0380 or (862) 298-0970 for international participants. Call replays will be available until November 10, 2020. NeoGenomics specializes in cancer genetics testing and operates multiple accredited laboratories across the U.S. and internationally.